77 results about "Pharmaceutical drug" patented technology

A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10 / IL-18 ratio and IL-10 / IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo- / non-responder.

Pharmaceutical compositions and treatments involving iNKT cell activation are provided.

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.

A controlled delivery drive mechanism includes a drug container having a barrel and a plunger seal; a drive housing within which at least initially partially resides a piston having an interface surface and a drive rack; and a power spring. The piston is configured to contact and axially translate the plunger seal within barrel. The mechanism may be configured to convert rotational movement of a drive pinion to axial translation of the drive rack, or to convert axial force of a linear power spring into torsional motion of a drive pinion. A regulating mechanism meters the drive pinion such that the piston is axially translated at a controlled rate. The drug container may contain a drug fluid within a drug chamber for drug delivery at a controlled rate. The regulating mechanism may be an escapement regulating mechanism. A drug delivery pump includes such controlled delivery drive mechanisms.

The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases by targeting a specific miRNA. In addition, the present invention relates to a kit for diagnosing neurodegenerative diseases. A miR-206 target found in the present invention, which is highly expressed in both animal models of Alzheimer's disease and human brain samples, is a substantial treatment target selected without artifact errors. An antisense oligonucleotide of the present invention as an inhibitor for miR-206 suggests a successful result in treatment of neurodegenerative diseases by targeting miRNA. The antisense oligonucleotide of the present invention inhibits the function of miR-206 to greatly increase the levels of BDNF and IGF-1 and to increase the regeneration of synapses, thereby treating neurodegenerative diseases, particularly Alzheimer's disease.

The invention relates to a di-substituted dinaphtho-[2,1-b:1',2'-d] furan derivative as well as a preparation method and an application thereof. The preparation method comprises the following steps of: synthesizing a series of di-substituted dinaphtho-[2,1-b:1',2'-d] furan derivatives through a series of reactions by using dibromo-dinaphtho-[2,1-b:1',2'-d] furan as the material. The invention further provides an application of the di-substituted dinaphtho-[2,1-b:1',2'-d] furan derivative in preparing an anti-tumor drug. By virtue of in-vitro pharmacological activity screening, the compound which is synthesized by the preparation method disclosed by the invention is shown to have an effect for inhibiting proliferation of tumor cells, wherein the compound 16 has an obvious inhibiting effect for the liver cancer cells SMMC-7721; and the IC50 value reaches 0.57mu M. Besides, the di-substituted dinaphtho-[2,1-b:1',2'-d] furan derivative is reasonable in design, simple and convenient in preparation method and strong in practicability.

The invention discloses a medicine for treating cold grasserie, comprising the raw medicine by weight parts: 50 to 150 parts of Tibet pleurospermum, 50 to 150 parts of Himalayan four-o'clock root, 50 to 150 parts of caltrop, 50 to 150 parts of Polygonati Rhizoma and 50 to 150 parts of asparagus; grain diameter of the medicine is 0.1 to 100 microns. The medicine of the invention has higher effective dissolution of medicine, medicine penetration power and bioavailability, and better medicine effect. The invention further discloses a method of preparing the medicine for treating cold grasserie and special quality examination method thereof such that the quality examination method effectively controls the stability of the medicine, and also effectively identifies the specificity of pharmaceutical ingredients in medicine.

The invention relates to the field of medicinal preparations, and in particular relates to a heparin-modified adriamycin liposome (Hep-DOX-Lip) preparation. The preparation is characterized by consisting of 1 part of adriamycin, 1-4 parts of heparin, 5-30 parts of soybean lecithin, 0.5-4 parts of cholesterol and 0.5 part of a cationic material. The invention further discloses a preparation method of the heparin-modified adriamycin liposome preparation. The heparin-modified adriamycin liposome preparation has an effect similar to pegylation, and can remarkably enhance the stability of an adriamycin liposome, prolong the in-vivo half-life period of a medicament, and enhance the bioavailability of the medicament. Meanwhile, the heparin-modified adriamycin liposome preparation can remarkably lower the toxic and side effects of chemotherapeutic drugs and enhance the compliance of patients.

The invention makes 24-site mutation on natural scorpion chlorine ion channel neurotoxin gene BmK CT according to the principle of Escherichia coli partial to codon, designs DNA sequence suitable to be expressed in Escherichia coli BL21 (DE3), adopts PCR technique to complete artificial synthesis of recombinant scorpion chlorine ion channel neurotoxin gene rBmK CTa. On this basis, it clones rBmK CTa into pEXSecI expression system to transfer in the BL21 (DE3), screens and obtains high-performance expressed bacterial strain, detects that the expressed product of the rBmK CTa accounts for 19.936% of the all-bacterium protein by SDS-PAGE electrophoresis, and by affinity chromatography, obtains purer protein with bioactivity, and can obtain 2.4mg protein from one liter culture liquor by purifying. The obtained modified recombinant scorpion chlorine ion channel neurotoxin has inhibition effect on neuroglia cell and can be used in preparing medicines curing diseases by inhibiting neuroglia cell and also be used in research on the space structure and pharmacological activity of scorpion neurotoxin.

The invention relates to a method for preparing quinsadu premixed agent which can resist illness and accelerate the growth of animal. The inventive premixed agent comprises 5 deals of quinsadu and 95 deals of carrier, wherein, the carrier can be one or the combination of zeolite powder, talcum powder, calcium carbonate powder, degreased rice bran powder, corn powder or amidon. The inventive premixed agent can be used in the forage additive of pig, chicken, duck, fish, calf and lamb, while the relative contents are 25-100mg, 25-200mg, 25-100mg, 25-200mg, 25-150mg, and 25-100mg. The invention can accelerate the growth, reduce the forage cost and improve the animal quality, while it can control the infection of digestive canal.

The invention relates to the field of microorganisms and especially relates to a bacterial strain, a construction method and an application thereof. The invention provides the bacterial strain for high-yield campesterol. An exogenous functional gene DHCR7 is guided into a chassis bacterial strain. Compared with plant extraction, the method for utilizing two yeast chassis bacterial strains including recombined brewer yeast and lipid yeast solution to produce campesterol has the advantages of low cost, few side products and low pollution; a feasible method is supplied for the industrial production of the campesterol. The basis is established for the biosynthesis of steride hormone drugs including downstream progesterone, 4AD and the like. The bacterial strain has guidance significance in acquiring high-yield campesterol through other microorganisms.

The invention relates to a blood disease related drug concentration detection method and application, and the method comprises the following steps: mixing a blood sample to be detected with a cell lysis solution or a buffer salt solution, adding a methanol solution of an isotope internal standard of the drug to be detected, oscillating, carrying out centrifugal separation, and collecting the supernatant; injecting the supernatant into a rapid liquid chromatography system for separation and analysis, then entering a triple quadrupole mass spectrometry detector, collecting and processing data through chromatographic software, and calculating the drug concentration in a blood sample to be detected. According to the blood disease related drug concentration detection method, according to the characteristics and clinical needs of the blood diseases, a scheme for detecting the blood concentration of the medicines related to the blood diseases is established, and the scheme has the advantagesthat a chromatographic column and a mobile phase do not need to be replaced, so that the detection efficiency and the operation convenience are greatly improved, and the method is suitable for large-scale clinical popularization.

The invention provides a use of an effective part of a traditional Chinese medicine in HIV latency-resistant treatment. Through an ingenious activity screening method, it is found that a traditional Chinese medicine rhizoma atractylodis macrocephalae has effects of resisting AIDS. Through a solvent extraction method, a gradient extraction method, a silica gel column chromatography and the combination with activity screening, an effective part of rhizoma atractylodis macrocephalae is determined and is prepared. The prepared effective part of rhizoma atractylodis macrocephalae can be used as an active component for resisting AIDS. The effective part of rhizoma atractylodis macrocephalae has an effect of HIV latency intervention, can be combined with a drug for resisting retroviruses, can accelerate the removal of latent virus reservoirs, and provides a novel approach for thorough curing of AIDS.

The invention discloses a kit for detecting valproic acid drug concentration in dry blood spots. The kit comprises a kit body, a first container, a calibrator card and a quality control card, whereinthe calibrator card is a blood spot collection card fixed with a group of valproic acid dry blood spot samples as dry blood spot calibration points, and the number of the dry blood spot calibration points is at least six, the quality control material card is a blood spot collection card fixed with at least one group of valproic acid dry blood spot samples as dry blood spot quality control points,the number of each group of dry blood spot quality control points is at least three, the first container is filled with an internal standard extracting solution, and an internal standard adopts isotopic substituted valproic acid. The invention further discloses a detection method of the kit. The kit provided by the invention has advantages of simple preparation of reagents, less required amount ofsamples, convenience in storage and transportation, rapid pretreatment, short analysis period, lower cost and the like, and is suitable for popularization in clinical conventional detection.

The invention discloses a traditional Chinese medicine preparation for treating the hyperplasia of mammary glands. The traditional Chinese medicine preparation accords with the theory of Chinese herb compatibility, aiming at the fundamental effect, the Indian kalimeris herb, abrus cantoniensis hance, spina gleditsiae, fructus liquidambaris, herba lycopi, musk, alangium leaf, trichosanthes kirilowii Maxim and farfugium japonicum are taken as the monarch drugs for promoting circulation and removing stasis, and dredging breast collaterals; the hemistepta lyrata, the seed of cowherb, felwort, adiantum caudatum, silkworm larva, dandelion and radix rhapontied are taken as the ministerial drugs for reducing swelling and resolving mass, and softening hard mass and stopping pain; the radix curcumae, radix polygonati officinalis, frankincense, rhizoma cyperi, tribulusterrestris, suncured ginseng, cistanche and salvia miltiorrhiza are taken as the adjuvant drugs with coordinating effect, for soothing the liver and regulating vital energy, nourishing the five organs, benefiting the vital essence and reinforcing the functions of the monarch drugs and the ministerial drugs and restraining the toxic side effect of the other medicines. Many medicines are simultaneously used with mild medical effect and permanent effectiveness, so that the functions of promoting qi circulation and stopping pain, removing toxicity and dispersing swelling, calming the liver and dispelling melancholy, and softening hardness to dissipate stagnation can be reached, and the hyperplasia of mammary glands can be cured.

The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.